ClinicalTrials.gg
CompletedNCT03197779Updated Jul 2, 2017

A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects

A Phase 1 interventional study of BMS-962212 and Aspirin in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 3 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-02.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2016, 10 years 9 months ago, and no results have been posted to the registry.
  • Registered 3 years 7 months after the study started (first participant enrolled Nov 2013, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
691
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing aspirin in Thrombosis — 2 open to participants now, 3 under way, none of them phase 3. Aspirin · Thrombosis.

Enrollment
5th of 28
691 · median 106
Started
2013
with 2 others
Phase 1
4 of 28
none open now
Registered
22nd of 28
by date
Lead sponsor
3 of 28
Bristol-Myers Squibb

Among the 28 studies testing aspirin in Thrombosis, this one is the 5th largest by enrollment, is one of 3 that started in 2013, is one of 4 in phase 1, and was the 22nd registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

2 of the 28 studies testing aspirin in Thrombosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing aspirin in Thrombosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following increasing doses of 2 h (Part A) and 5 day (Part B) continuous IV infusions of BMS-962212 in healthy subjects across the expected pharmacodynamic dose range.

03

Conditions studied

  • Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Healthy subjects as determined by no deviation from normal in medical history, physical examination, , and clinical laboratory determinations
  • (BMI) of 18 to 32 kg/m2 inclusive [as calculated by BMI = weight (kg)/ [height (m)]2
  • This study permits the re-enrollment of a subject that has discontinued the study as a pre-treatment failure (ie, subject has not been randomized / has not been treated). If re-enrolled, the subject must be re-consented
  • Men, ages 18 to 45 years, inclusive; women, ages 18-45, who are not of
  • Women must not be breastfeeding

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • Women of
  • Current or recent (within 3 months of study drug administration) gastrointestinal disease which by the judgment of the Investigator may increase a subject's risk of gastrointestinal bleeding (e.g., peptic or gastric ulcer disease, severe gastritis, history of gastrectomy)
  • Any major surgery within 12 weeks of study drug administration
  • History of blood transfusion, bleeding event(s), or documented genetic bleeding diathesis or thrombophilia
  • For Aspirin Containing Arm Participants Only: Known allergy to non-steroidal anti-inflammatory drugs or history of intolerance or abnormal sensitivity to aspirin (e.g gastrointestinal intolerance, bruising or bleeding, aspirin induced breathing difficulties or nasal polyps)

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
691 participants (actual)

Study arms

  • Experimental
    BMS-962212 Two Hour Administration

    Intravenous administered over 2 hours of BMS-962212

    Drug: BMS-962212

  • Experimental
    BMS-962212 5 Day Administration

    Intravenous administered over 5 days of BMS-962212

    Drug: BMS-962212

  • Experimental
    BMS-962212 and Aspirin

    BMS-962212 intravenous administration, followed by aspirin oral administration, then combination administration of BMS-962212 and aspirin

    Drug: BMS-962212 · Drug: Aspirin

  • Placebo comparator
    Placebo and Aspirin

    Placebo intravenous administration, followed by aspirin, then combination administration of placebo and aspirin

    Drug: Aspirin · Other: Placebo

  • Placebo comparator
    Placebo

    Placebo intravenous administration

    Other: Placebo

Interventions

  • DrugBMS-962212

    Intravenous Infusion administration over 2 hours or 5 days

  • Oral administration

  • OtherPlacebo

    Oral administration

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE)

    measured by incidence

    Time frame: Up to 8 days

  2. Serious Adverse Events (SAE)

    measured by incidence

    Time frame: Up to 8 days

  3. Discontinuation due to AE

    measured by incidence

    Time frame: Up to 8 days

  4. Death

    measured by incidence

    Time frame: Up to 8 days

  5. AE of clinically significant bleeding

    measured by incidence

    Time frame: Up to 8 days

  6. AE of clinically significant infusion reaction

    measured by incidence

    Time frame: Up to 8 days

  7. AE of clinically significant vital signs

    measured by incidence

    Time frame: Up to 8 days

  8. QTcF intervals - QT interval corrected for heart rate according to Fridericia's formula

    measured by ECG

    Time frame: Up to 8 days

  9. QRS - The interval from the beginning of the Q wave and the end of the S wave

    measured by ECG

    Time frame: Up to 8 days

  10. PR - The interval from the beginning of the P wave to the beginning of the QRS complex

    measured by ECG

    Time frame: Up to 8 days

  11. 24-hour cardiac monitoring

    measured by telemetry

    Time frame: Up to 6 days

  12. Glomerular filtration rate (GFR)

    measured by iohexol administration plasma clearance and the Chronic Kidney Disease-Epidemiology Collaborative Group (CKD EPI) equation

    Time frame: Up to 8 days

  13. Cystatin-C

    measured by serum biomarkers

    Time frame: Up to 8 days

  14. Neutrophil gelatinase-associated lipocalin (NGAL)

    measured by urine biomarkers

    Time frame: Up to 8 days

  15. Monocyte chemoattractant protein-1 (MCP-1)

    measured by urine biomarkers

    Time frame: Up to 8 days

07

Study locations

3 sites
  • Wcct Global, Llc
    Cypress, California 90630, United States
  • California Clinical Trials Medical Group
    Glendale, California 91206, United States
  • Parexel International - Baltimore Epcu
    Baltimore, Maryland 21225, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Feb 2016, 26 months.

Of 30 phase 1 interventional studies under Thrombosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2017
First posted
Jun 23, 2017
StartActual
Nov 18, 2013
Primary completionActual
Feb 2, 2016
CompletionActual
Jan 24, 2017
Last update
Jul 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03197779
Responsible party
Sponsor
First posted
Jun 23, 2017
Start date
Nov 18, 2013
Primary completion
Feb 2, 2016
Completion
Jan 24, 2017
Last update
Jul 2, 2017

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion